Testosterone and benign prostatic hyperplasia
Copyright policy )Testosterone and benign prostatic hyperplasia
The use of testosterone to treat the symptoms of late-onset hypogonadal men has increased recently due to patient and physician awareness. However, concerns regarding the effect of testosterone on the prostate, in particular any possible effect on the risk of prostate cancer have prompted further research in this regard. Surprisingly, numerous retrospective or small, randomized trials have pointed to a possible improvement in male lower urinary tract symptoms (LUTS) in patients treated with testosterone. The exact mechanism of this improvement is still debated but may have a close relationship to metabolic syndrome. For the clinician, the results of these studies are promising but do not constitute high levels of evidence. A thorough clinical examination (including history, examination and laboratory testing of testosterone) should be undertaken before considering the diagnosis of late-onset hypogonadism or instigating treatment for it. Warnings still remain on the testosterone supplement product labels regarding the risk of urinary retention and worsening LUTS, and these should be explained to patients.
- Cornell University United States
- Weill Cornell Medical College in Qatar Qatar
- UNSW Sydney Australia
Urologic Diseases, Male, Aging, anzsrc-for: 1114 Paediatrics and Reproductive Medicine, Hormone Replacement Therapy, Clinical Trials and Supportive Activities, Prostatic Hyperplasia, 610, 32 Biomedical and Clinical Sciences, anzsrc-for: 3215 Reproductive medicine, anzsrc-for: 1103 Clinical Sciences, anzsrc-for: 32 Biomedical and Clinical Sciences, Lower Urinary Tract Symptoms, Clinical Research, Risk Factors, 616, Humans, Eunuchism, Testosterone, 3202 Clinical Sciences, Cancer, anzsrc-for: 3211 Oncology and Carcinogenesis, Invited Review, Prostate Cancer, Age Factors, 3211 Oncology and Carcinogenesis, Diseases of the genitourinary system. Urology, Urinary Bladder Neck Obstruction, benign prostatic hyperplasia; lower urinary tract symptoms; metabolic syndrome X; testosterone; urinary bladder neck obstruction, Treatment Outcome, Quality of Life, anzsrc-for: 3202 Clinical Sciences, RC870-923
Urologic Diseases, Male, Aging, anzsrc-for: 1114 Paediatrics and Reproductive Medicine, Hormone Replacement Therapy, Clinical Trials and Supportive Activities, Prostatic Hyperplasia, 610, 32 Biomedical and Clinical Sciences, anzsrc-for: 3215 Reproductive medicine, anzsrc-for: 1103 Clinical Sciences, anzsrc-for: 32 Biomedical and Clinical Sciences, Lower Urinary Tract Symptoms, Clinical Research, Risk Factors, 616, Humans, Eunuchism, Testosterone, 3202 Clinical Sciences, Cancer, anzsrc-for: 3211 Oncology and Carcinogenesis, Invited Review, Prostate Cancer, Age Factors, 3211 Oncology and Carcinogenesis, Diseases of the genitourinary system. Urology, Urinary Bladder Neck Obstruction, benign prostatic hyperplasia; lower urinary tract symptoms; metabolic syndrome X; testosterone; urinary bladder neck obstruction, Treatment Outcome, Quality of Life, anzsrc-for: 3202 Clinical Sciences, RC870-923
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).46 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!